HIV Strains Targeted 99% by New Antibody Engineered by Sanofi

Published Date : Sep 25, 2017

An antibody engineered by Sanofi, a U.S. National Institutes of Health and pharmaceutical company, scientists has been discovered to be effective against 99.0% of human immunodeficiency virus (HIV) strains. The antibody has also been found to be capable of avoiding infection in primates. The deadly virus has been observed to find it difficult to resist the effects of the antidote since it attacks its three vital parts. The engineered antidote has been honored as an “exciting breakthrough” by the International Acquired Immunodeficiency Syndrome (AIDS) Society (IAS).

First Human Trials of HIV Antibody to Get Off Ground in 2018

According to chief scientific officer, Dr. Gary Nabel, at Sanofi, the antidote has been providing a 99.0% coverage with greater breadth and potent than any naturally occurring single antibody under discovery. Nabel has also said that the antibody has been providing coverage even at low concentrations. Other scientists around the world have been focusing on neutralizing antibodies as a method to prevent HIV in the first place or to treat the deadly infection.

Sometime next year, there could be a likely commencement of human trials of the antidote to check if the antibody is as effective in treating or preventing HIV in humans as well.

The collaborative study between Sanofi and the National Institutes of Health published in Science had included 24 monkeys that were injected with HIV. After the tri-specific antibody had been given to the animal participants, none developed the virus. Professor Linda-Gail Bekker, the IAS president, has said that the “super-engineered” antibody could embrace more applications than imagined till date and seem to surpass the natural.